Cannabis, a complex plant: different compounds and different effects on individuals

被引:374
作者
Atakan, Zerrin [1 ]
机构
[1] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, DeCrespigny Pk, London SE5 8AF, England
关键词
Cannabis; delta-9-tetrahydrocannabinol; cannabidiol; tetrahydrocannabivarin; endocannabinoids; individual sensitivity to cannabis;
D O I
10.1177/2045125312457586
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cannabis is a complex plant, with major compounds such as delta-9-tetrahydrocannabinol and cannabidiol, which have opposing effects. The discovery of its compounds has led to the further discovery of an important neurotransmitter system called the endocannabinoid system. This system is widely distributed in the brain and in the body, and is considered to be responsible for numerous significant functions. There has been a recent and consistent worldwide increase in cannabis potency, with increasing associated health concerns. A number of epidemiological research projects have shown links between dose-related cannabis use and an increased risk of development of an enduring psychotic illness. However, it is also known that not everyone who uses cannabis is affected adversely in the same way. What makes someone more susceptible to its negative effects is not yet known, however there are some emerging vulnerability factors, ranging from certain genes to personality characteristics. In this article we first provide an overview of the biochemical basis of cannabis research by examining the different effects of the two main compounds of the plant and the endocannabinoid system, and then go on to review available information on the possible factors explaining variation of its effects upon different individuals.
引用
收藏
页码:241 / 254
页数:14
相关论文
共 106 条
[1]  
Anderson BM, 2010, J PSYCHOACTIVE DRUGS, V42, P413
[2]   Early cannabis use and Schizotypal Personality Disorder Symptoms from adolescence to middle adulthood [J].
Anglin, Deidre M. ;
Corcoran, Cheryl M. ;
Brown, Alan S. ;
Chen, Henian ;
Lighty, Quenesha ;
Brook, Judith S. ;
Cohen, Patricia R. .
SCHIZOPHRENIA RESEARCH, 2012, 137 (1-3) :45-49
[3]   Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study [J].
Arseneault, L ;
Cannon, M ;
Poulton, R ;
Murray, R ;
Caspi, A ;
Moffitt, TE .
BRITISH MEDICAL JOURNAL, 2002, 325 (7374) :1212-1213
[4]  
Atha M, 2005, INDEPENDENT DRUG MON
[5]   Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death [J].
Athanasiou, Andriam ;
Clarke, Anna B. ;
Turner, Amy E. ;
Kumaran, Nethia M. ;
Vakilpour, Sara ;
Smith, Paul A. ;
Bagiokou, Dimitra ;
Bradshaw, Tracey D. ;
Westwell, Andrew D. ;
Fang, Lin ;
Lobo, Dileep N. ;
Constantinescu, Cris S. ;
Calabrese, Vittorio ;
Loesch, Andrzej ;
Alexander, Stephen P. H. ;
Clothier, Richard H. ;
Kendall, David A. ;
Bates, Timothy E. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 364 (01) :131-137
[6]   Cannabis-induced psychosis-like experiences are associated with high schizotypy [J].
Barkus, E. J. ;
Stirling, J. ;
Hopkins, R. S. ;
Lewis, S. .
PSYCHOPATHOLOGY, 2006, 39 (04) :175-178
[7]   Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension [J].
Bátkai, S ;
Pacher, P ;
Osei-Hyiaman, D ;
Radaeva, S ;
Liu, J ;
Harvey-White, J ;
Offertáler, L ;
Mackie, K ;
Rudd, MA ;
Bukoski, RD ;
Kunos, G .
CIRCULATION, 2004, 110 (14) :1996-2002
[8]   CARDIOVASCULAR AND METABOLIC CONSIDERATIONS IN PROLONGED CANNABINOID ADMINISTRATION IN MAN [J].
BENOWITZ, NL ;
JONES, RT .
JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (8-9) :S214-S223
[9]   Imaging the Neural Effects of Cannabinoids: Current Status and Future Opportunities for Psychopharmacology [J].
Bhattacharyya, S. ;
Crippa, J. A. ;
Martin-Santos, R. ;
Winton-Brown, T. ;
Fusar-Poli, P. .
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (22) :2603-2614
[10]  
Bhattacharyya S, 2012, MOL PSYCHIAT